Innovative Pricing and Payment Models for Health Technologies
By João L. Carapinha
October 22, 2024
The article titled “Design and Features of Pricing and Payment Schemes for Health Technologies,” centers on the crucial topic of pricing and payment (P&P) schemes for health technologies in the healthcare sector. The discussion encompasses key aspects that influence this domain, providing insights on how these schemes can effectively address current challenges.
Objective
The article aims to map existing types of pricing and payment schemes for health technologies while proposing a new, flexible, need-driven classification system that enhances understanding and applicability.
Context
Given the increasing clinical and financial uncertainty in the healthcare sector, innovative pricing and payment schemes are being explored as potential solutions to these persistent challenges.
Current Schemes
The article conducts a scoping review to identify and categorize the various P&P schemes currently in use for health technologies. This includes different models such as:
Fixed pricing
Value-based pricing
Risk-sharing agreements
Pay-for-performance models
Subscription-based models
Proposed Classification
The authors propose a new classification system that is both flexible and need-driven. This system is designed to help policymakers, healthcare providers, and manufacturers navigate the complex landscape of P&P schemes more effectively. It considers various factors, including the type of health technology and the specific needs of different healthcare systems.
Key Features
The article highlights several key features of effective pricing and payment schemes, which include:
Flexibility: The ability to adapt to evolving healthcare needs and financial constraints.
Value-Based: Schemes that tie payments to actual health outcomes or to the value delivered by the health technology.
Risk Management: Mechanisms that distribute risk among manufacturers, payers, and providers.
Innovation Incentives: Schemes designed to encourage the development and adoption of new health technologies.
Implications
The proposed classification and analysis of P&P schemes have significant implications for healthcare policy, practice, and research. It can aid in:
Improving the sustainability of healthcare systems
Enhancing access to innovative health technologies
Aligning payments with health outcomes
Reducing financial uncertainty for various stakeholders involved.
In summary, the article provides a comprehensive framework for understanding and improving the design and implementation of P&P schemes in the healthcare sector, ultimately serving as a vital tool in addressing current challenges. The focus on pricing and payment schemes is essential for fostering effective health technology utilization and ensuring ongoing innovation.
🚀 Are pharmaceutical companies’ DTC telehealth partnerships reshaping healthcare for better or worse?
Recent findings from the “DTC Investigation 2025” report reveal key insights into the high prescription rates and potential risks of these digital platforms operated by giants like Pfizer and Eli Lilly. Alarmingly, inadequate clinical safeguards raise questions about patient safety, prescribing practices, and cost implications.
Dive into this critical discussion about the intersection of digital health and pharmaceutical practices, and explore what it means for the future of patient care.
🌟 How can personalized medicine transform breast cancer treatment in Spain?
The recent rollout of the MAF Test breast cancer in leading Spanish hospitals is set to revolutionize patient care by enabling targeted treatment strategies. This innovative molecular assay not only identifies patients who will benefit from bisphosphonates but also spares those for whom the treatment may be harmful, ultimately improving outcomes for thousands.
Dive into the article to discover how this approach aligns with global trends in oncology and enhances healthcare resource allocation.
🌟 Are we on the brink of transforming breast cancer treatment?
NICE’s latest guidance endorsing ribociclib in combination with an aromatase inhibitor marks a significant advancement for adults facing high-risk early breast cancer. This decision not only promises enhanced survival outcomes but also expands treatment options for patients historically limited to conventional therapies.
Dive into the details of this important development and learn how it may revolutionize patient care in the oncology landscape.
When you partner with Syenza, it’s like a Nuclear Fusion.
Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in
health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.
